During drug manufacturing, the analytical support function provides scientific and product quality assurance to the predominantly chemical/mechanical functions of manufacturing and packaging activities. Analytical support to manufacturing involves, on a continuing basis, translation of current regulations, evolving technical guidances and pharmacopeia, and analytical procedures and laboratory operations, to meet the scientific, regulatory, and quality expectations for product manufacture. More specifically, analytical testing using appropriate techniques, validated methods, and modem equipment is central to the assurance of the quality of raw materials, in-process controls, and finished product. This article addresses the analytical support required for pharmaceutical manufacturing from active pharmaceutical ingredient (API) synthesis and drug development and approval, through manufacturing and shelf life of the drug product. Key elements of analytical support to manufacturing that are necessary to maintain a state of control during pharmaceutical manufacturing are discussed. Current Good Manufacturing Practice (GMP) and quality systems that are specifically relevant to analytical support to manufacturing are emphasized.
Federal Food, Drug, and Cosmetic Act (Public Law No. 75–717 52 Stat. 1040) 1938.
2.
International Conference on Harmonization.Guidance for Industry—Q7A: Good Manufacturing Practice (GMP) Guidance for Active Pharmaceutical Ingredients. Geneva, Switzerland: International Conference on Harmonization; August 2001.
3.
US Food and Drug Administration.Current Good Manufacturing Practice for the Manufacture, Processing, Packaging and Holding of Drugs, 21 CFR—Parts 210 and 211. Rockville, MD: US Food and Drug Administration; March 1998.
4.
US Food and Drug Administration.Drug Manufacturing Inspections—Compliance Program Guidance Manual. Rockville, MD: US Food and Drug Administration; October 2000.
5.
DeCampWH. The impact of polymorphism on drug development—A regulator's point of view. Am Pharm Rev.2001; 4(3):70–77.
6.
The Pharmaceutical Codex.Principles and Practices of Pharmaceutics. London, UK: The Pharmaceutical Press; 1994.
7.
DavidovichMMuellerRRaghavanKRanadiveSVitezISarsfieldBDiMarcoJGougoutasJNewmanA. The role of X-ray diffraction as a powerful tool in characterization of various hydrants of a drug substance. Am Pharm Rev.2001; 4(1):53–60.
8.
United States Pharmacopeial Convention, Inc. The United States Pharmacopeia (USP)/The National Formulary (NF). USP 25, NF 20. Rockville, MD: United States Pharmacopeial Convention, Inc.; January 2002.
9.
International Conference on Harmonization.Q3A (R): Impurities in New Drug Substances. Geneva, Switzerland: International Conference on Harmonization; July 2000.
10.
International Conference on Harmonization.Q3B (R): Impurities in New Drug Products. Geneva, Switzerland: International Conference on Harmonization; July 2000.
11.
International Conference on Harmonization.Q3C: Impurities: Residual Solvents. Geneva, Switzerland: International Conference on Harmonization; December 1997.
12.
International Conference on Harmonization. Q2A: Guidelines on Validation of Analytical Procedures: Definitions and Terminology. Geneva, Switzerland: International Conference on Harmonization; March 1995.
13.
International Conference on Harmonization.Q2B: Guidelines on the Validation of Analytical Procedures: Methodology. Geneva, Switzerland: International Conference on Harmonization; May 1997.
14.
International Conference on Harmonization.Q1A (R): Stability Testing of New Drug Substances and Products. Geneva, Switzerland: International Conference on Harmonization; April 2000.
15.
International Conference on Harmonization.Q1B: Photostability Testing of New Drug Substances and Products. Geneva, Switzerland: International Conference on Harmonization; November 1996.
16.
International Conference on Harmonization.Q1C: Stability Testing of New Dosage Forms. Geneva, Switzerland: International Conference on Harmonization; May 1997.
17.
International Conference on Harmonization.Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. Geneva, Switzerland: International Conference on Harmonization; September 2000.
18.
US Food and Drug Administration.Guidance for Industry—Stability Testing of Drug Substances and Drug Products. Rockville, MD: US Food and Drug Administration; June 1998.
19.
US Food and Drug Administration.Guidance for Industry—Content and Format of Investigational New Drug Applications for Phase 1 Studies of Drugs, Including Well Characterized, Therapeutic, Biotechnology Derived Products. Rockville, MD: US Food and Drug Administration; November 1995.
20.
US Food and Drug Administration.Guidance for Industry—INDs for Phase 2 and 3 Studies of Drugs, Including Well Characterized, Therapeutic, Biotechnology Derived Products, Chemistry, Manufacturing and Controls Content and Format. Rockville, MD: US Food and Drug Administration; February 1999.
21.
21 CFR Part 312. Investigational New Drug Application. Rockville, MD: US Food and Drug Administration; April 1994.
22.
21 CFR Part 314. Application for FDA Approval to Market a New Drug or an Antibiotic Drug. Rockville, MD: US Food and Drug Administration; April 1994.
23.
US Food and Drug Administration.Guidance for Industry—Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate—Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System. Rockville, MD: US Food and Drug Administration; August 2000.
24.
International Conference on Harmonization.Q6A (R): Specifications: Test Procedures and Acceptance Criteria for New Drug Substance and New Drug Products: Chemical Substances. Geneva, Switzerland: International Conference on Harmonization; December 2000.
25.
US Food and Drug Administration.Guidance for Industry—Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation. Rockville, MD: US Food and Drug Administration; July 2002.
26.
US Food and Drug Administration.Guidance for Industry—Investigation of Out of Specification (OOS) Test Results for Pharmaceutical Production. Rockville, MD: US Food and Drug Administration; September 1998.
27.
GentryAE. Methodical evaluation of OOS results—a problem solving approach. Am Pharm Rev.2001; 4(4):78–81.
28.
VelagaletiRHallidayJNolandP. Analytical Support for Pharmaceutical Manufacturing—Translating Regulations and Guidelines into Laboratory Operations. In: Pharmaceutical Packaging and Manufacturing Sourcer. London, UK: Samedan Ltd. Pharmaceutical Publishing; March 1999.
29.
US Food and Drug Administration.Guidance for Industry—Immediate Release Solid Oral Dosage Forms, Scale-up, and Post-approval Changes: In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Rockville, MD: US Food and Drug Administration; November 1995.
30.
US Food and Drug Administration.Guidance for Industry—Nonsterile Semisolid Dosage Forms, Scale-up, and Post-approval Changes: In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Rockville, MD: US Food and Drug Administration; May 1997.
31.
US Food and Drug Administration.Guidance for Industry—Changes to the Approved NDA or ANDA. Rockville, MD: US Food and Drug Administration; November 1999.
32.
US Food and Drug Administration.Reviewer Guidance—Validation of Chromatographic Methods. Rockville, MD: US Food and Drug Administration; November 1994.
33.
Health Protection Branch.Acceptable Methods. Drugs Directorate Guidelines. Ottawa, Canada: Health Protection Branch. Health and Welfare Canada; July 1992.
34.
BankerU.Pharmaceutical Dissolution Testing. New York, NY: Marcel Dekker, Inc.; 1992.
35.
StoreyDE. The role of dissolution testing in the design of immediate release dosage forms. Drug Inf J.1996; 30:1039–1044.
36.
US Food and Drug Administration.Guide to Inspections of Validation of Cleaning Processes. Rockville, MD: US Food and Drug Administration; May 1993.
37.
US Food and Drug Administration.Guide to Inspections of Bulk Pharmaceutical Chemicals. Rockville, MD: Food and Drug Administration; May 1994.
38.
KirschRB. Validation of analytical methods in pharmaceutical cleaning assessment and validation. Pharma Tech Supp. 1998; 22:40–45.
39.
US Food and Drug Administration.Guidance for Industry—Container Closure Systems for Packaging Human Drugs and Biologics, Chemistry, Manufacturing and Controls Documentation. Rockville, MD: US Food and Drug Administration; May 1999.
40.
Electronic Records and Electronic Signatures. 21 CFR PART 11. Final Rule. Federal Register. 1997; 62:13430–13466.
41.
US Food and Drug Administration.CDER News Along the Pike. Office of Pharmaceutical Sciences (OPS) Forms Advisory Group for Process Analytical Technologies. Rockville, MD: US Food and Drug Administration; July 24, 2002:8(2).
